Close
  Indian J Med Microbiol
 

Figure 1: Important steps in repurposing of AZM as a neurotherapeutic agent. Additional work in animal models is needed to both improve AZM’s efficacy and develop outcome measures feasible for use in non-invasive human studies. Application of these outcome measures in the patient population already taking AZM near time of injury could provide key evidence for the transition of AZM into clinical trials and use as a therapeutic for SCI. AZM: Azithromycin; SCI: spinal cord injury.

Figure 1: Important steps in repurposing of AZM as a neurotherapeutic agent.
Additional work in animal models is needed to both improve AZM’s efficacy and develop outcome measures feasible for use in non-invasive human studies. Application of these outcome measures in the patient population already taking AZM near time of injury could provide key evidence for the transition of AZM into clinical trials and use as a therapeutic for SCI. AZM: Azithromycin; SCI: spinal cord injury.